Table 1. Demographics and viro-immunological status of the population studied.
| Parameter | Value |
| Age in years, median (IQR) | 45.6 (41.4–50.0) |
| Men, n (%) | 32 (76.2) |
| Means of HIV-1 infection | |
| MsM (%) | 16 (38.1) |
| HTSX (%) | 9 (21.4) |
| IDU (%) | 17 (40.5) |
| Years since diagnosis, years, median (IQR) | 14 (10–21) |
| Smokers, n (%) | 25 (59.5) |
| Prior AIDS, n (%) | 27 (64.3) |
| HCV co-infection, n (%) | 26 (61.9) |
| HCV treatment completed, n (%) | 5 (31.2) |
| HBV co-infection, n (%) | 1 (2.4) |
| Baseline CD4, median (IQR), cells/mm3 | 603 (389–901) |
| CD4 increase (IQR), cells/mm3 | 412 (258–573) |
| Nadir CD4 cell count <100 cells/mm3 (%) | 14 (33.3) |
| Nadir CD4 cell count <200 cells/mm3 (%) | 29 (69.0) |
| Baseline viral load, median (IQR), log10, copies/ml | 1.28 (1.28–1.28) |
| Maximum viral load ≥5 log10, copies/ml (%) | 26 (61.9) |
| Viral load decrease, median (IQR), log10, copies/ml | 4.1 (3.6–4.7) |
All values expressed as median (IQR = interquartile range) unless otherwise specified, MsM = men who have sex with men, HTSX = heterosexuals, IDU = intravenous drug users, AIDS = acquired immune deficiency syndrome, HCV = hepatitis C virus, HBV = hepatitis B virus, CD4 increase = current CD4-CD4 prior to starting of antiretroviral therapy, IQR = interquartile range.